AI in Cancer Diagnostics
Nov 27, 2024
AI in Cancer Diagnostics: Paving the Way for Early Detection and Precision Treatment
Artificial Intelligence (AI) is revolutionizing numerous fields, and healthcare, particularly cancer diagnostics, is no exception. With the promise of faster, more accurate diagnoses, AI is transforming how clinicians detect, diagnose, and treat cancer. By leveraging vast amounts of medical data, advanced algorithm...
Read More...
Oct 24, 2024
iRhythm’s Zio® AT Device Improvements Receive FDA Clearance; Epitel Adds REMI AI Device to Portfolio with Fourth FDA 510(k); SeaStar Medical Advances Acute Kidney Injury Trial, Approaches Interim Analysis; Endospan Completes Primary Enrollment for TRIOMPHE Study of NEXUS® Stent Graft; Boston Scientific Enhances FARAPULSE™ PFA with New Cardiac Mapping Technology; GE HealthCare Debuts CareIntellect to Support Oncologists with AI-Enhanced Patient Insights
iRhythm Technologies Received FDA 510(k) Clearance for Design Updates Previously Made to Its Zio® AT Device On October 21, 2024, iRhythm Technologies, Inc., a leading digital healthcare company specializing in solutions to detect, predict, and prevent disease, announced that the U.S. Food and Drug Administ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
